Cargando…

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy

HIGHLIGHTS: Cardiac-specific Dsg2 deletion induces excessive cardiac fibrosis in mice. Fenofibrate alleviates cardiac fibrosis in CS-Dsg2(−/−) mice. Cardiac-specific activation of PPARα ameliorates cardiac fibrosis in CS-Dsg2(−/−) mice. The inhibitory effect of PPARα on cardiac fibrosis is mediated...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zirui, Zhao, Yawen, Tao, Tian, Guo, Wenying, Liu, Ruonan, Huang, Jingmin, Xu, Geyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601208/
https://www.ncbi.nlm.nih.gov/pubmed/36291052
http://dx.doi.org/10.3390/cells11203184
_version_ 1784817002035019776
author Qiu, Zirui
Zhao, Yawen
Tao, Tian
Guo, Wenying
Liu, Ruonan
Huang, Jingmin
Xu, Geyang
author_facet Qiu, Zirui
Zhao, Yawen
Tao, Tian
Guo, Wenying
Liu, Ruonan
Huang, Jingmin
Xu, Geyang
author_sort Qiu, Zirui
collection PubMed
description HIGHLIGHTS: Cardiac-specific Dsg2 deletion induces excessive cardiac fibrosis in mice. Fenofibrate alleviates cardiac fibrosis in CS-Dsg2(−/−) mice. Cardiac-specific activation of PPARα ameliorates cardiac fibrosis in CS-Dsg2(−/−) mice. The inhibitory effect of PPARα on cardiac fibrosis is mediated by STAT3 and TGF-β /SMAD3 signaling. PPARα is a promising target for the intervention of ACM by ameliorating cardiac fibrosis. ABSTRACT: Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disease characterized by progressive fibro-fatty replacement of cardiac myocytes. Up to now, the existing therapeutic modalities for ACM are mostly palliative. About 50% of ACM is caused by mutations in genes encoding desmosomal proteins including Desmoglein-2 (Dsg2). In the current study, the cardiac fibrosis of ACM and its underlying mechanism were investigated by using a cardiac-specific knockout of Dsg2 mouse model. Methods: Cardiac-specific Dsg2 knockout (CS-Dsg2(−/−)) mice and wild-type (WT) mice were respectively used as the animal model of ACM and controls. The myocardial collagen volume fraction was determined by histological analysis. The expression levels of fibrotic markers such as α-SMA and Collagen I as well as signal transducers such as STAT3, SMAD3, and PPARα were measured by Western blot and quantitative real-time PCR. Results: Increased cardiac fibrosis was observed in CS-Dsg2(−/−) mice according to Masson staining. PPARα deficiency and hyperactivation of STAT3 and SMAD3 were observed in the myocardium of CS-Dsg2(−/−) mice. The biomarkers of fibrosis such as α-SMA and Collagen I were upregulated after gene silencing of Dsg2 in HL-1 cells. Furthermore, STAT3 gene silencing by Stat3 siRNA inhibited the expression of fibrotic markers. The activation of PPARα by fenofibrate or AAV9-Pparα improved the cardiac fibrosis and decreased the phosphorylation of STAT3, SMAD3, and AKT in CS-Dsg2(−/−) mice. Conclusions: Activation of PPARα alleviates the cardiac fibrosis in ACM.
format Online
Article
Text
id pubmed-9601208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96012082022-10-27 Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy Qiu, Zirui Zhao, Yawen Tao, Tian Guo, Wenying Liu, Ruonan Huang, Jingmin Xu, Geyang Cells Article HIGHLIGHTS: Cardiac-specific Dsg2 deletion induces excessive cardiac fibrosis in mice. Fenofibrate alleviates cardiac fibrosis in CS-Dsg2(−/−) mice. Cardiac-specific activation of PPARα ameliorates cardiac fibrosis in CS-Dsg2(−/−) mice. The inhibitory effect of PPARα on cardiac fibrosis is mediated by STAT3 and TGF-β /SMAD3 signaling. PPARα is a promising target for the intervention of ACM by ameliorating cardiac fibrosis. ABSTRACT: Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disease characterized by progressive fibro-fatty replacement of cardiac myocytes. Up to now, the existing therapeutic modalities for ACM are mostly palliative. About 50% of ACM is caused by mutations in genes encoding desmosomal proteins including Desmoglein-2 (Dsg2). In the current study, the cardiac fibrosis of ACM and its underlying mechanism were investigated by using a cardiac-specific knockout of Dsg2 mouse model. Methods: Cardiac-specific Dsg2 knockout (CS-Dsg2(−/−)) mice and wild-type (WT) mice were respectively used as the animal model of ACM and controls. The myocardial collagen volume fraction was determined by histological analysis. The expression levels of fibrotic markers such as α-SMA and Collagen I as well as signal transducers such as STAT3, SMAD3, and PPARα were measured by Western blot and quantitative real-time PCR. Results: Increased cardiac fibrosis was observed in CS-Dsg2(−/−) mice according to Masson staining. PPARα deficiency and hyperactivation of STAT3 and SMAD3 were observed in the myocardium of CS-Dsg2(−/−) mice. The biomarkers of fibrosis such as α-SMA and Collagen I were upregulated after gene silencing of Dsg2 in HL-1 cells. Furthermore, STAT3 gene silencing by Stat3 siRNA inhibited the expression of fibrotic markers. The activation of PPARα by fenofibrate or AAV9-Pparα improved the cardiac fibrosis and decreased the phosphorylation of STAT3, SMAD3, and AKT in CS-Dsg2(−/−) mice. Conclusions: Activation of PPARα alleviates the cardiac fibrosis in ACM. MDPI 2022-10-11 /pmc/articles/PMC9601208/ /pubmed/36291052 http://dx.doi.org/10.3390/cells11203184 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Qiu, Zirui
Zhao, Yawen
Tao, Tian
Guo, Wenying
Liu, Ruonan
Huang, Jingmin
Xu, Geyang
Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title_full Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title_fullStr Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title_full_unstemmed Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title_short Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
title_sort activation of pparα ameliorates cardiac fibrosis in dsg2-deficient arrhythmogenic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601208/
https://www.ncbi.nlm.nih.gov/pubmed/36291052
http://dx.doi.org/10.3390/cells11203184
work_keys_str_mv AT qiuzirui activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT zhaoyawen activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT taotian activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT guowenying activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT liuruonan activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT huangjingmin activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy
AT xugeyang activationofpparaamelioratescardiacfibrosisindsg2deficientarrhythmogeniccardiomyopathy